Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ZOLOFT

Summary for Tradename: ZOLOFT

Suppliers: see list13
patent expirations by year for

Pharmacology for Tradename: ZOLOFT

Clinical Trials for: ZOLOFT

Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects
Status: Completed Condition: Healthy

Special Investigation Of Long Term Use Of Sertraline.
Status: Completed Condition: Depression; Panic Disorder

Special Investigation Of J Zoloft For Panic Disorder Patients
Status: Completed Condition: Panic Disorder

Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression
Status: Completed Condition: Depression; Unspecified Adult Solid Tumor, Protocol Specific

An 8-week, Open-label Study to Evaluate the Effect of Sertraline on Polysomnogram in Depressive Patients With Insomnia
Status: Completed Condition: Depression

A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions
Status: Completed Condition: Healthy

Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery
Status: Enrolling by invitation Condition: Roux en Y Gastric Bypass Surgery

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions
Status: Completed Condition: Healthy

Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
sertraline hydrochloride
CONCENTRATE;ORAL020990Dec 7, 1999RXYes6,727,283*PED<disabled>Y<disabled>
sertraline hydrochloride
CONCENTRATE;ORAL020990Dec 7, 1999RXYes7,067,555*PED<disabled>Y<disabled>
sertraline hydrochloride
TABLET;ORAL019839Dec 30, 1991DISCNNo<disabled><disabled>
sertraline hydrochloride
TABLET;ORAL019839Dec 30, 1991RXNo<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZOLOFT

Drugname Dosage Strength RLD Submissiondate
sertraline hydrochlorideTablets150 mg and 200 mgZoloft11/9/2005

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology